1 / 3

FDA Approved Biosimilar Products - Insights10

According to the Insights10 market research report, the global biosimilar market is mirroring this growth, with a projected value of a staggering $97.4Bn by 2030. This significant increase represents a CAGR of 18.32%, building upon a robust $30Bn market in 2023. This surge is driven by several factors, including the rising prevalence of chronic diseases and the cost-effectiveness of biosimilars

Insights10
Télécharger la présentation

FDA Approved Biosimilar Products - Insights10

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FDA-APPROVED BIOSIMILAR PRODUCTS Source: FDA Selarsdi (ustekinumab-aekn) Tyenne (tocilizumab-aazg) Jubbonti & Wyost (denosumab-bbdz) Reference Product: Stelara (ustekinumab) Reference Product: Actemra (tocilizumab) Reference Product: Prolia and Xgeva (denosumab) April 2024 February 2024 March 2024 Simlandi (adalimumab-ryvk) Avzivi (bevacizumab-tnjn) Wezlana (ustekinumab-auub) Reference Product: Humira (adalimumab) Reference Product: Avastin (bevacizumab) Reference Product: Stelara (ustekinumab) February 2024 December 2023 October 2023 Tofidence (tocilizumab-bavi) Tyruko (natalizumab-sztn) Yuflyma (adalimumab-aaty) Reference Product: Actemra (tocilizumab) Reference Product: Tysabri (natalizumab) Reference Product: Humira (adalimumab) September 2023 August 2023 May 2023 Idacio (adalimumab-aacf) Vegzelma (bevacizumab-adcd) Stimufend (pegfilgrastim-fpgk) Reference Product: Humira (adalimumab) Reference Product: Avastin (bevacizumab) Reference Product: Neulasta (pegfilgrastim) December 2022 September 2022 September 2022 Cimerli (ranibizumab-eqrn) Fylnetra (pegfilgrastim-pbbk) Alymsys (bevacizumab-maly) Reference Product: Lucentis (ranibizumab) Reference Product: Neulasta (pegfilgrastim) Reference Product: Avastin (bevacizumab) August 2022 May 2022 April 2022 *Biosimilar Name,

  2. Releuko (filgrastim-ayow) Yusimry (adalimumab-aqvh) Rezvoglar (insulin glargine-aglr) Reference Product: Neupogen (filgrastim) Reference Product: Humira (adalimumab) Reference Product: Lantus (insulin glargine) February 2022 December 2021 December 2021 Byooviz (ranibizumab-nuna) Semglee (Insulin glargine-yfgn) Riabni (rituximab-arrx) Reference Product: Lucentis (ranibizumab) Reference Product: Lantus (Insulin glargine) Reference Product: Rituxan (rituximab) September 2021 July 2021 December 2020 Hulio (adalimumab-fkjp) Nyvepria (pegfilgrastim-apgf) Avsola (infliximab-axxq) Reference Product: Humira (adalimumab) Reference Product: Neulasta (pegfilgrastim) Reference Product: Remicade (infliximab) July 2020 June 2020 December 2019 Abrilada (adalimumab-afzb) Ziextenzo (pegfilgrastim-bmez) Hadlima (adalimumab-bwwd) Reference Product: Humira (adalimumab) Reference Product: Neulasta (pegfilgrastim) Reference Product: Humira (adalimumab) November 2019 November 2019 July 2019 Ruxience (rituximab-pvvr) Zirabev (bevacizumab-bvzr) Kanjinti (trastuzumab-anns) Reference Product: Rituxan (rituximab) Reference Product: Avastin (bevacizumab) Reference Product: Herceptin (trastuzumab) July 2019 June 2019 June 2019 Eticovo (etanercept-ykro) Trazimera (trastuzumab-qyyp) Ontruzant (trastuzumab-dttb) Reference Product: Enbrel (etanercept) Reference Product: Herceptin (trastuzumab) Reference Product: Herceptin (trastuzumab) April 2019 March 2019 January 2019 *Biosimilar Name,

  3. Herzuma (trastuzumab-pkrb) Truxima (rituximab-abbs) Udenyca (pegfilgrastim-cbqv) Reference Product: Herceptin (trastuzumab) Reference Product: Rituxan (rituximab) Reference Product: Neulasta (pegfilgrastim) December 2018 November 2018 November 2018 Hyrimoz (adalimumab-adaz) Nivestym (filgrastim-aafi) Fulphila (pegfilgrastim-jmdb) Reference Product: Humira (adalimumab) Reference Product: Neupogen (filgrastim) Reference Product: Neluasta (pegfilgrastim) October 2018 July 2018 June 2018 Retacrit (epoetin alfa-epbx) Ixifi (infliximab-qbtx) Ogivri (trastuzumab-dkst) Reference Product: Epogen (epoetin-alfa) Reference Product: Remicade (infliximab) Reference Product: Herceptin (trastuzumab) May 2018 December 2017 December 2017 Mvasi (Bevacizumab-awwb) Cyltezo (Adalimumab-adbm) Renflexis (Infliximab-abda) Reference Product: Avastin (bevacizumab) Reference Product: Humira (adalimumab) Reference Product: Remicade (infliximab) September 2017 August 2017 May 2017 Amjevita (Adalimumab -atto) Erelzi (Etanercept-szzs) Inflectra (Infliximab-dyyb) Reference Product: Humira (adalimumab) Reference Product: Enbrel (etanercept) Reference Product: Remicade (infliximab) September 2016 August 2016 April 2016 Zarxio (Filgrastim-sndz) Reference Product: Neupogen (filgrastim) March 2015 *Biosimilar Name,

More Related